{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:02:54Z","timestamp":1786989774888,"version":"build-2736575974"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:00:00Z","timestamp":1578096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["08-1286-001"],"award-info":[{"award-number":["08-1286-001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2209-16"],"award-info":[{"award-number":["2209-16"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC-81172066"],"award-info":[{"award-number":["NSFC-81172066"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC-81472858"],"award-info":[{"award-number":["NSFC-81472858"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC-915291003"],"award-info":[{"award-number":["NSFC-915291003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.gendis.2019.12.014","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T12:30:23Z","timestamp":1578659423000},"page":"291-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-4720","authenticated-orcid":false,"given":"Yong","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gendis.2019.12.014_bib1","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.gendis.2019.12.014_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.gendis.2019.12.014_bib3","first-page":"19","article-title":"Report of cancer epidemiology in China, 2015","volume":"41","author":"Zheng","year":"2019","journal-title":"Zhonghua Zhongliu Zazhi"},{"key":"10.1016\/j.gendis.2019.12.014_bib4","first-page":"571","article-title":"Liver cancer incidence and mortality in China: temporal trends and projections to 2030","volume":"30","author":"Zheng","year":"2018","journal-title":"Chin J Canc Res"},{"issue":"4","key":"10.1016\/j.gendis.2019.12.014_bib5","first-page":"271","article-title":"Cancer treatment and survivorship statistics","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.gendis.2019.12.014_bib6","doi-asserted-by":"crossref","first-page":"12122","DOI":"10.1002\/jcp.28048","article-title":"Therapeutics for advanced hepatocellular carcinoma: recent advances, current dilemma, and future directions","volume":"234","author":"Zhu","year":"2019","journal-title":"J Cell Physiol"},{"issue":"11","key":"10.1016\/j.gendis.2019.12.014_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.21037\/tgh.2018.10.16","article-title":"Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment","volume":"3","author":"Siu","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"14","key":"10.1016\/j.gendis.2019.12.014_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.21037\/atm.2018.06.14","article-title":"Precision oncology in liver cancer","volume":"6","author":"Sullivan","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.gendis.2019.12.014_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.canlet.2017.10.008","article-title":"Precision diagnosis and treatment of liver cancer in China","volume":"412","author":"Fu","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2019.12.014_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/hpb.12212","article-title":"Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter","volume":"16","author":"Dai","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.gendis.2019.12.014_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jso.21415","article-title":"Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma","volume":"101","author":"Lee","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.gendis.2019.12.014_bib12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jgh.12470","article-title":"Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area","volume":"29","author":"Kwak","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jjco\/hyx180","article-title":"Chemotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"48","author":"Ikeda","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.gendis.2019.12.014_bib14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gendis.2019.12.014_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gendis.2019.12.014_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gendis.2019.12.014_bib17","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"Global burden of liver disease: the major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.gendis.2019.12.014_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.gendis.2019.12.014_bib19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jhep.2014.11.025","article-title":"Roles of alcohol consumption in fatty liver: a longitudinal study","volume":"62","author":"Moriya","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gendis.2019.12.014_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gendis.2019.12.014_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/ijmr.IJMR_1456_17","article-title":"Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: an increasing concern","volume":"149","author":"Dhamija","year":"2019","journal-title":"Indian J Med Res"},{"issue":"7","key":"10.1016\/j.gendis.2019.12.014_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib23","article-title":"Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges","volume":"1","author":"Berkan-Kawi\u0144ska","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.gendis.2019.12.014_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000002361","article-title":"Should patients with NAFLD\/NASH Be surveyed for HCC?","volume":"103","author":"Reig","year":"2019","journal-title":"Transplantation"},{"issue":"370","key":"10.1016\/j.gendis.2019.12.014_bib25","first-page":"1","article-title":"Contribution of hepatitis B virus infection to the aggressiveness of primary liver cancer: a clinical epidemiological study in eastern China","volume":"9","author":"Yang","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2019.12.014_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib27","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gendis.2019.12.014_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","article-title":"The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Canc"},{"key":"10.1016\/j.gendis.2019.12.014_bib29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s11427-016-0351-y","article-title":"Regional immunity in tissue homeostasis and diseases","volume":"59","author":"Tian","year":"2016","journal-title":"Sci China Life Sci"},{"issue":"6","key":"10.1016\/j.gendis.2019.12.014_bib30","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2015.02.038","article-title":"The yin and yang of evasion and immune activation in HCC","volume":"62","author":"Makarova-Rusher","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib31","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jhep.2016.01.028","article-title":"The role of innate Immunity in the immunopathology and treatment of HBV infection","volume":"64","author":"Maini","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib32","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib33","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanism of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association For The Study Of The","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1473-3099(07)70264-5","article-title":"Therapeutic strategies in the management of patients with chronic hepatitis B virus infection","volume":"8","author":"Papatheodoridis","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.gendis.2019.12.014_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterol"},{"issue":"1","key":"10.1016\/j.gendis.2019.12.014_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12876-019-0981-5","article-title":"Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"10.1016\/j.gendis.2019.12.014_bib38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/apt.13779","article-title":"Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B","volume":"44","author":"Marcellin","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.gendis.2019.12.014_bib39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jcv.2014.08.008","article-title":"Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive Chronic hepatitis B: a randomized trial","volume":"61","author":"Cheng","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.gendis.2019.12.014_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3350\/cmh.2016.0086","article-title":"Risk score model for the development of hepatocellular carcinoma in treatment-na\u00efve patients receiving oral antiviral treatment for chronic hepatitis B","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin and Mol Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systemic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib43","first-page":"240","article-title":"Hepatitis B and hepatitis C reactivation in the biologic era","volume":"2","author":"Bojito-Marrero","year":"2014","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib44","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis B virus cccDNA-The holy grail to hepatitis B cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coviro.2018.04.006","article-title":"Perspectives and limitations for nucleo(t)side analogs in future HBV therapies","volume":"30","author":"Levrero","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.gendis.2019.12.014_bib46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013:findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gendis.2019.12.014_bib47","first-page":"84","article-title":"China's efforts to shed its title of Leader in liver disease","volume":"1","author":"Li","year":"2007","journal-title":"Drug Discov Ther"},{"issue":"11","key":"10.1016\/j.gendis.2019.12.014_bib48","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1136\/gutjnl-2018-316091","article-title":"HBV infection-induced liver cirrhosis development in dual-humanized mice with human bone mesenchymal stem cell transplantation","volume":"68","author":"Yuan","year":"2019","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.gendis.2019.12.014_bib49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/17460441.2018.1473372","article-title":"Recent advances in the discovery and development of TRL ligand as novel therapeutics for chronic HBV and HIV infections","volume":"13","author":"Du","year":"2018","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.gendis.2019.12.014_bib50","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1038\/s41598-018-23525-w","article-title":"Direct anti-viral properties of TLR ligands against HBV replication in immune-competent hepatocytes","volume":"8","author":"Lucifora","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.gendis.2019.12.014_bib51","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2017.12.007","article-title":"Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism","volume":"68","author":"Niu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2019.12.014_bib52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2019.12.014_bib53","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gendis.2019.12.014_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CJI.0000000000000190","article-title":"Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy","volume":"41","author":"Tajmir-Riahi","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.gendis.2019.12.014_bib55","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","article-title":"Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action","volume":"23","author":"Neilan","year":"2018","journal-title":"The Oncologist"},{"key":"10.1016\/j.gendis.2019.12.014_bib56","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13046-018-0777-4","article-title":"Immune checkpoint therapy in liver cancer","volume":"37","author":"Xu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2019.12.014_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17460441.2017.1255195","article-title":"The current status and future directions of hepatitis B anti-viral drug discovery","volume":"12","author":"Tang","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.gendis.2019.12.014_bib58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2015.08.005","article-title":"Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting anti-viral therapeutics","volume":"122","author":"Guo","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.gendis.2019.12.014_bib59","series-title":"Primary Liver Cancer","first-page":"1","year":"1998"},{"issue":"2","key":"10.1016\/j.gendis.2019.12.014_bib60","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/hep.29561","article-title":"A large-scale, multicenter serum metabolite biomarker identification study for early detection of hepatocellular carcinoma","volume":"67","author":"Luo","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gendis.2019.12.014_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000455","article-title":"Immunotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"3","author":"Okusaka","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.gendis.2019.12.014_bib62","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/14712598.2018.1499722","article-title":"Recent developments with immunotherapy for hepatocellular carcinoma","volume":"18","author":"Waidmann","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.gendis.2019.12.014_bib63","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gendis.2019.12.014_bib64","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gendis.2019.12.014_bib65","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.gendis.2019.12.014_bib66","doi-asserted-by":"crossref","first-page":"52866","DOI":"10.18632\/oncotarget.17905","article-title":"Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager","volume":"8","author":"Bi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.gendis.2019.12.014_bib67","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/jgo.2017.02.01","article-title":"Systemic therapy for advanced hepatocellular carcinoma: an update","volume":"8","author":"Desai","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2019.12.014_bib68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.it.2019.03.004","article-title":"Cancer immunoediting by innate lymphoid cells","volume":"40","author":"Wagner","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.gendis.2019.12.014_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.smim.2015.11.002","article-title":"Cancer immunotherapy targeting neoantigens","volume":"28","author":"Lu","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1016\/j.gendis.2019.12.014_bib70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13073-017-0408-2","article-title":"Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies","volume":"9","author":"Hartmaier","year":"2017","journal-title":"Genome Med"},{"issue":"7747","key":"10.1016\/j.gendis.2019.12.014_bib71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","article-title":"Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma","volume":"567","author":"Jiang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2019.12.014_bib72","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.vaccine.2016.05.073","article-title":"Personalized cancer vaccines: targeting the cancer mutanome","volume":"35","author":"Zhang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.gendis.2019.12.014_bib73","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5582\/ddt.2015.01054","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"9","author":"Li","year":"2015","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.gendis.2019.12.014_bib74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-017-0712-x","article-title":"The biology of Hepatocellular carcinoma: implications for genomic and immune therapies","volume":"16","author":"Khemlina","year":"2017","journal-title":"Mol Cancer"},{"key":"10.1016\/j.gendis.2019.12.014_bib75","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12029-018-0121-4","article-title":"Hepatocellular carcinoma: review of targeted and immune therapies","volume":"49","author":"da Motta Girardi","year":"2018","journal-title":"J Gastrointest Cancer"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304220300088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304220300088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:24:18Z","timestamp":1762449858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304220300088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2352304220300088"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2019.12.014","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2019.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chongqing Medical University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}